NCT05673850View on ClinicalTrials.gov

Association Between HER2 Status and pCR Rate in ER-positive Breast Cancer Receiving Neoadjuvant Endocrine or Chemotherapy

CompletedOBSERVATIONAL
Enrollment

518

Participants

Timeline

Start Date

May 1, 2022

Primary Completion Date

August 1, 2022

Study Completion Date

October 1, 2022

Conditions
Breast Neoplasms
Interventions
DRUG

NET or NCT

In this study, we included 518 ER-positive BC patients who received either neoadjuvant endo-crine therapy (NET) or neoadjuvant chemotherapy (NCT).

Trial Locations (1)

000013

Peking University Cancer Hospital, Haidian

All Listed Sponsors
lead

Peking University

OTHER